Lexaria Bioscience Corp.
Financial highlights
| Metric | FY 08/31/25 | FY 08/31/24 | FY 08/31/23 | FY 08/31/22 | FY 08/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 |
| Cost of revenue | $2,720 | $4,822 | $31,500 | $71,841 | $175,346 |
| Gross profit | $703,203 | $459,456 | $194,708 | $183,556 | $547,392 |
| Research and development | $8.2M | $2.4M | $3.7M | $1.8M | $1.3M |
| Operating expenses | $12.6M | $6.2M | $6.7M | $6.8M | $6.2M |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M | -$5.7M |
| Interest expense | — | $7,760 | $0 | — | — |
| Pretax income | -$11.9M | -$5.8M | -$6.7M | -$7.4M | -$4.2M |
| Income tax expense | — | — | — | $0 | $6,093 |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M | -$4.0M |
| Balance Sheet | |||||
| Cash and equivalents | — | — | — | $5.8M | $10.9M |
| Current assets | $3.5M | $7.9M | $2.2M | $7.0M | $12.4M |
| Total assets | $4.2M | $8.9M | $3.1M | $7.8M | $13.3M |
| Current liabilities | $1.5M | $1.1M | $267,735 | $194,036 | $153,276 |
| Total liabilities | $1.6M | $1.2M | $403,908 | $201,437 | $203,265 |
| Stockholders' equity | $3.0M | $8.0M | $3.0M | $7.9M | $13.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$10.5M | -$5.0M | -$5.9M | -$4.9M | -$4.0M |
| Depreciation and amortization | $51,225 | $42,448 | $145,397 | $102,718 | $111,718 |
| Stock-based compensation | $859,494 | $492,236 | $170,382 | $752,591 | $410,007 |
| Capital expenditure | $24,646 | $43,014 | $33,748 | $49,192 | $0 |
| Free cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | -$4.0M |
| Impairments | $247,364 | $57,836 | $106,761 | $0 | — |
Shares outstanding 24.8M · Free float 76.9%
Annual filing data through FY ended August 31, 2025; float as of July 13, 2026.